SONM
DNA X, Inc.
Next earnings Aug 6, 2026
Last earnings +4.2% on 2026-05-20
$5.70
▲ +20.76%$5.70▼ -75.07%
over 1Y
L $2.75EODHDH $31.68
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+20.8%
1W+16.6%
1M+40.0%
3M+73.8%
YTD+97.9%
1Y-75.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity -6.36x); but revenue fell -45.6% YoY.
DNA X, Inc. shows $50.9M in FY2024 revenue (-45.6% YoY), a -40.6% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $54.6M | $69.8M | $93.6M | $50.9M | — |
| Gross profit | $6.41M | $11.6M | $19.3M | $9.92M | — |
| Operating income | -$38.0M | -$14.3M | $513K | -$3.10M | -$5.41M |
| Net income | -$38.6M | -$14.1M | -$90.0K | -$33.6M | -$20.7M |
| Diluted EPS | — | -$0.49 | -$0.02 | -$128.37 | -$28.58 |
| Net margin | -70.8% | -20.2% | -0.1% | -66.1% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$17.3M
EV / EBITDA—
EV / Sales0.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-243.5%
FCF yield-279.8%
Quality & risk
ROIC (est.)—
Free cash flow-$23.7M
Total debt$10.1M
Net cash-$8.83M
Altman Z-Score-9.37 distress
Piotroski F-Score2/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-76.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-06-04). Worth a closer look.
Recent filings
all on EDGAR ↗EFFECTFiling2026-06-11open ↗POS AMFiling2026-06-08open ↗8-KPeriod ending 2026-05-292026-06-04open ↗8-KPeriod ending 2026-05-202026-05-27open ↗10-QPeriod ending 2026-03-312026-05-20open ↗8-KPeriod ending 2026-05-202026-05-20open ↗NT 10-QPeriod ending 2026-03-312026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-K/APeriod ending 2025-12-312026-04-30open ↗8-KPeriod ending 2026-04-272026-04-30open ↗10-KPeriod ending 2025-12-312026-04-15open ↗8-KPeriod ending 2026-04-142026-04-15open ↗
Frequently asked
- Is DNA X, Inc. (SONM) a buy?
- SONM currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -6.36x); but revenue fell -45.6% YoY.
- What is DNA X, Inc.'s quality score?
- SONM scores 44.94117647058823/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001178697, latest 10-Q filed 2026-05-20) · EODHD · as of 6/26/2026, 4:33:52 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.